Biogen (NASDAQ: BIIB)
Biogen Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Biogen Company Info
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
News & Analysis
Why Biogen Stock Leaped Nearly 5% Higher Today
The company came out swinging with its first set of quarterly earnings for this year.
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
Getting its Alzheimer's medicine approved in the European Union could be big.
These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street
Nice gains could be on the way for three stocks if analysts are right.
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
The real competitive battle is about to begin, and it will last a long time.
3 Struggling Stocks Investors Shouldn't Buy on the Dip
These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better.
Is Biogen Stock a Buy Now?
It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
Buying a biotech is a good move, but it might not be enough to entice investors.
Better Buy: Biogen vs. Eli Lilly
This battle of biotech giants has a clear winner.
Valuation
Earnings Transcripts
Biogen (BIIB) Q1 2024 Earnings Call Transcript
BIIB earnings call for the period ending March 31, 2024.
Biogen (BIIB) Q4 2023 Earnings Call Transcript
BIIB earnings call for the period ending December 31, 2023.
Biogen (BIIB) Q3 2023 Earnings Call Transcript
BIIB earnings call for the period ending September 30, 2023.
Biogen (BIIB) Q2 2023 Earnings Call Transcript
BIIB earnings call for the period ending June 30, 2023.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.